Centre Suisse d'Electronique et de Microtechnique (CSEM)

Michael E. Porter; Willis M. Emmons III; Christian  Fenner

Case | HBS Case Collection | February 2003 (Revised March 2006)

Centre Suisse d'Electronique et de Microtechnique (CSEM)

by Michael E. Porter, Willis M. Emmons III and Christian Fenner

Abstract

Le Centre Suisse d'Electronique et de Microtechnique S.A. (CSEM)--the Swiss Center for Electronics and Microtechnology--was a major nonprofit research institution located in Neuchatel, Switzerland, with roots in the Swiss watch industry. CSEM maintained close links to several Swiss universities, and over time, the center's activities expanded to include basic and applied research, contract production, and technology consulting. By the late 1990s, CSEM began spinning off promising commercial ventures and incorporating them as for-profit companies. In 2001, CEO Thomas Hinderling wondered whether any adjustments in CSEM's strategy were necessary or desirable going forward.

Keywords: Cooperation; Technology; Alliances; Research and Development; Performance Productivity; Innovation and Invention; Nonprofit Organizations; Electronics Industry; Switzerland;

Language: English

Format: Print

7 pages

Educators Purchase

Citation:

Porter, Michael E., Willis M. Emmons III, and Christian Fenner. "Centre Suisse d'Electronique et de Microtechnique (CSEM)." Harvard Business School Case 703-438, February 2003. (Revised March 2006.)

Since its establishment in 2005, Hamburg’s Martini Klinik had single mindedly focused on prostate cancer care with a commitment to measure long-term health outcomes for every patient. A wholly owned subsidiary of the University Hospital Hamburg, Martini Klinik was a “hospital in a hospital” in close proximity to other medical departments and services. By 2019, Martini Klinik had become the largest prostate cancer treatment program in the world with 8,000 outpatient cases and more than 2,500 surgical cases annually. Patients came from all over Germany and from around the world. A new and expanded facility was under construction to have the capacity to manage more patients with prostate cancer.

Currently, few health care providers measure and report their patient outcomes, which leads to several problems. Attempts to introduce price transparency without outcomes transparency could trigger a “race to the bottom.” Should Medicare coverage be expanded to non-elderly populations, its much lower reimbursements will create pressure on providers to lower their spending in ways that produce even worse outcomes. Even without Medicare expansion, the lack of systematic outcomes measurement has made the migration from fee-for-service to value-based reimbursements, especially bundled payments, less effective and more difficult to implement. Hidden variation in outcomes prevents providers from learning from others how to produce better outcomes for their patients. We propose that the Congress elected in November 2020 mandate the Centers for Medicare and Medicaid Services to begin requiring outcomes measurement by all providers reimbursed under government Medicare and Medicaid programs.

We are entering a new stage of understanding of the linkage between investment performance and social impact. Previous approaches, such as socially responsible investing and environmental, social, and governance (ESG) screening, have obscured the opportunities for higher growth, profitability, and competitive advantage that come from creating shared value: addressing social and environmental issues as integral to a company’s core strategic positioning. A shared value approach to investing can deliver superior shareholder returns, but capturing that value will require very different practices on the part of both corporate leaders and investors.

Faculty & Research

Centre Suisse d'Electronique et de Microtechnique (CSEM)

Abstract

Citation:

About the Authors

More from these Authors